Eli Lilly and Company (LLY) 78.31 $LLY
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 10 mins ago
Cramer will be watching for earnings from Apple, General Dynamics and Starbucks.
AMZN: 599.03 (+35.12), BUD: 118.73 (+1.46), CY: 10.25 (+0.49), GD: 148.28 (+1.03), GPRO: 29.15 (+0.43), MCK: 186.96 (+5.52), EA: 74.92 (+0.38), BRCM: 53.13 (+0.60), SKX: 31.64 (-14.55), PFE: 34.05 (+0.72), STZ: 136.20 (-1.61), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98), PEN: 38.15 (+1.43), SBUX: 62.61 (+1.12), ABC: 93.13 (+0.33), WBA: 89.96 (+1.33), MRK: 52.88 (+0.87), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84), CVX: 91.24 (-0.38), AAPL: 119.08 (+3.58)
Jim Cramer Favors Eli Lilly, Calls P&G a Catch-Up Trade
at The Street - Fri Oct 23, 2:13PM CDT
TheStreet's Jim Cramer shares his thoughts on Procter & Gamble, FireEye, Twitter, Eli Lilly and more, when answering viewers questions.
JNJ: 100.31 (+0.78), FEYE: 27.23 (-2.14), GILD: 107.99 (+0.39), LLY: 78.31 (+1.33), PG: 77.03 (+2.18), TWTR: 30.28 (+1.13), AAPL: 119.08 (+3.58)
Forget Merck's Headline Numbers and Focus on These Key Points Instead
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 23, 1:02PM CDT
Source: Merck. Next week is shaping up to be an important week for earnings, with a huge percentage of the S&P 500 companies reporting their results. One such company that's bound to garner a lot of attention, which also happens to be a...
MRK: 52.88 (+0.87), LLY: 78.31 (+1.33)
Research and Markets: Muscle Atrophy - Pipeline Review, H2 2015 Featuring Acceleron Pharma, Biogen, Eli Lilly and Company, Fate Therapeutics & Rigel Pharmaceuticals
Business Wire - Fri Oct 23, 11:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmzxll/muscle_atrophy) has announced the addition of the "Muscle Atrophy - Pipeline Review, H2 2015" report to their offering.
FATE: 3.73 (+0.46), LLY: 78.31 (+1.33), RIGL: 2.63 (-0.27), XLRN: 26.17 (+0.86)
Why Valeant Isn’t Enron -- or Like Any Other Drug Stock
at The Street - Fri Oct 23, 10:55AM CDT
Whether the allegations against Valeant are true or not, they shouldn't be tainting most other biotech and drug stocks. That's because Valeant is in its own unique universe.
VRX: 116.16 (+6.29), PFE: 34.05 (+0.72), ABBV: 50.34 (+2.07), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98)
Muscle Atrophy - Pipeline Review, H2 2015 Featuring Acceleron Pharma, Biogen, Eli Lilly and Company, Fate Therapeutics & Rigel Pharmaceuticals
M2 - Fri Oct 23, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z4zdzz/muscle_atrophy) has announced the addition of the "Muscle Atrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Acceleron Pharma, Inc. - Biogen, Inc. - Eli Lilly and Company - Fate Therapeutics, Inc. - Rigel Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/z4...le_atrophy
FATE: 3.73 (+0.46), LLY: 78.31 (+1.33), RIGL: 2.63 (-0.27), XLRN: 26.17 (+0.86)
Global Anal Cancer Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Oct 23, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5v4vqf/anal_cancer) has announced the addition of the "Anal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advaxis, Inc. - Amgen Inc. - Eli Lilly and Company - ISA Pharmaceuticals B.V. - MedImmune, LLC - Novartis AG - Sun Pharma Advanced Research Company Ltd. Drug Profiles - axalimogene filolisbac - Cell Therapy for HPV Associated Cancers - durvalumab tremelimumab - ISA-101 - paclitaxel albumin free - panitumumab - PDR-001 - prexasertib For more information visit http://www.researchandmarkets.com/research/5v...nal_cancer
ADXS: 10.77 (+0.47), AMGN: 155.75 (+3.44), LLY: 78.31 (+1.33), NVS: 92.98 (+0.55)
Sell These 5 Scary Stocks Before It's Too Late
at The Street - Fri Oct 23, 6:03AM CDT
It's time to unload these toxic stocks from your portfolio.
NFLX: 100.04 (+2.72), SAFM: 69.41 (+0.50), LLY: 78.31 (+1.33), VZ: 46.16 (+0.27), PANW: 159.20 (-6.94)
Proof-of-concept Study of Fruquintinib in Non-small Cell Lung Cancer Triggers Milestone Payment
PR Newswire - Fri Oct 23, 1:46AM CDT
Hutchison China MediTech Limited ("Chi-Med"
(AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP" , its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourth quarter of 2015, from its partner Eli Lilly and Company ("Lilly" .
LLY: 78.31 (+1.33)
Eli Lilly Q3 Earnings, Guidance Beat On Cost Control
at Investor's Business Daily - Thu Oct 22, 6:09PM CDT
Big pharma Eli Lilly beat Q3 earnings expectations and raised EPS guidance early Thursday, while the company's CEO defended the industry's drug pricing. Lilly's revenue was more of a mixed bag, as the firm continues to struggle with foreign-exchange...
MRK: 52.88 (+0.87), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98), NVS: 92.98 (+0.55)
Shire (SHPG) Gets CRL for Dry Eye Disease Drug from FDA
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 3:35PM CDT
Shire (SHPG) received a complete response letter from the FDA for its new drug application for lifitegrast for the treatment of dry eye disease.
ADHD: 6.73 (+0.45), SHPG: 213.55 (+9.28), LLY: 78.31 (+1.33), NVS: 92.98 (+0.55)
Lilly (Eli) & Co (LLY) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Thu Oct 22, 2:43PM CDT
The following Lilly (Eli) & Co (LLY) conference call took place on October 22, 2015, 09:00 AM ET. This is a transcript of that earnings call:
LLY: 78.31 (+1.33)
Stocks Rally as eBay, Texas Instruments Lead Tech Sector
at The Street - Thu Oct 22, 1:12PM CDT
Stocks hover near session highs by mid-afternoon Thursday after better-than-expected earnings from eBay and Texas Instruments boost the tech sector.
MMM: 155.79 (-0.21), XLB: 45.02 (+0.37), AXP: 74.59 (+2.09), FB: 102.19 (+2.52), LLY: 78.31 (+1.33), AKS: 2.66 (+0.02), PYPL: 34.99 (+0.20), INTC: 34.90 (+0.50), CTXS: 81.14 (+0.56), UA: 92.02 (-1.79), LYB: 94.16 (-0.35), EBAY: 28.16 (+0.58), BHP: 35.75 (+0.37), TXN: 58.98 (+0.89), COST: 155.74 (-2.41), MCD: 112.59 (+1.72), XLK: 43.83 (+1.19), GOOGL: 719.33 (+38.19), CAT: 71.75 (+0.87), MSFT: 52.87 (+4.84), RIO: 38.29 (+0.33), AAPL: 119.08 (+3.58), DOW: 50.32 (+0.40), BABA: 75.62 (+4.63)
Eli Lilly Beats on 3Q Earnings by Wide Margin, Ups View
Arpita Dutt - Zacks Investment Research - Thu Oct 22, 10:30AM CDT
Eli Lilly (LLY) raised its earnings outlook after posting better-than-expected third quarter earnings.
NVO: 55.72 (+2.07), AZN: 31.36 (+0.29), ABBV: 50.34 (+2.07), LLY: 78.31 (+1.33)
Stocks Jump as Europe Rallies on ECB Stimulus Hopes
at The Street - Thu Oct 22, 10:16AM CDT
Stocks extend session highs Thursday, following in the footsteps of European markets which rallied on hopes of more stimulus from the European Central Bank.
MMM: 155.79 (-0.21), AXP: 74.59 (+2.09), PYPL: 34.99 (+0.20), LLY: 78.31 (+1.33), LULU: 48.49 (-3.84), CTXS: 81.14 (+0.56), UAL: 59.68 (+3.63), UA: 92.02 (-1.79), EBAY: 28.16 (+0.58), TXN: 58.98 (+0.89), COST: 155.74 (-2.41), MCD: 112.59 (+1.72), CAT: 71.75 (+0.87), DOW: 50.32 (+0.40)
Eli Lilly (LLY) Stock Gains in Pre-Market Trading on Earnings Beat, Raised Guidance
at The Street - Thu Oct 22, 8:03AM CDT
Eli Lilly (LLY) stock is increasing in pre-market trading on Thursday, after the company announced its 2015 third quarter financial results and raised its financial outlook.
LLY: 78.31 (+1.33)
Stock Futures Rise as McDonald's Posts Surprise Beat
at The Street - Thu Oct 22, 7:42AM CDT
Stock futures are higher Thursday after better-than-expected earnings from McDonald's.
MMM: 155.79 (-0.21), AXP: 74.59 (+2.09), LLY: 78.31 (+1.33), PYPL: 34.99 (+0.20), LULU: 48.49 (-3.84), CTXS: 81.14 (+0.56), UAL: 59.68 (+3.63), UA: 92.02 (-1.79), EBAY: 28.16 (+0.58), TXN: 58.98 (+0.89), MCD: 112.59 (+1.72), COST: 155.74 (-2.41), CAT: 71.75 (+0.87), DOW: 50.32 (+0.40)
Eli Lilly (LLY) Beats on Q3 Earnings, Revenues Fall Short
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 7:00AM CDT
Eli Lilly's (LLY) third quarter earnings surpassed expectations by a wide margin.
LLY: 78.31 (+1.33)
Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Thu Oct 22, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdtss/breast_cancer) has announced the addition of the "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023. A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III) Chapter 5 Recommendations Chapter 6 Company Profiles - AstraZeneca plc - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Novartis International AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/5x...ast_cancer
PFE: 34.05 (+0.72), AZN: 31.36 (+0.29), LLY: 78.31 (+1.33), GSK: 42.11 (+0.67), NVS: 92.98 (+0.55)
Lilly beats 3Q profit forecasts
Automated Insights - Thu Oct 22, 5:33AM CDT
INDIANAPOLIS (AP) _ Eli Lilly and Co. (LLY) on Thursday reported third-quarter net income of $799.7 million.
LLY: 78.31 (+1.33)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 10 mins ago
Cramer will be watching for earnings from Apple, General Dynamics and Starbucks.
AMZN: 599.03 (+35.12), BUD: 118.73 (+1.46), CY: 10.25 (+0.49), GD: 148.28 (+1.03), GPRO: 29.15 (+0.43), MCK: 186.96 (+5.52), EA: 74.92 (+0.38), BRCM: 53.13 (+0.60), SKX: 31.64 (-14.55), PFE: 34.05 (+0.72), STZ: 136.20 (-1.61), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98), PEN: 38.15 (+1.43), SBUX: 62.61 (+1.12), ABC: 93.13 (+0.33), WBA: 89.96 (+1.33), MRK: 52.88 (+0.87), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84), CVX: 91.24 (-0.38), AAPL: 119.08 (+3.58)
Jim Cramer Favors Eli Lilly, Calls P&G a Catch-Up Trade
at The Street - Fri Oct 23, 2:13PM CDT
TheStreet's Jim Cramer shares his thoughts on Procter & Gamble, FireEye, Twitter, Eli Lilly and more, when answering viewers questions.
JNJ: 100.31 (+0.78), FEYE: 27.23 (-2.14), GILD: 107.99 (+0.39), LLY: 78.31 (+1.33), PG: 77.03 (+2.18), TWTR: 30.28 (+1.13), AAPL: 119.08 (+3.58)
Forget Merck's Headline Numbers and Focus on These Key Points Instead
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 23, 1:02PM CDT
Source: Merck. Next week is shaping up to be an important week for earnings, with a huge percentage of the S&P 500 companies reporting their results. One such company that's bound to garner a lot of attention, which also happens to be a...
MRK: 52.88 (+0.87), LLY: 78.31 (+1.33)
Research and Markets: Muscle Atrophy - Pipeline Review, H2 2015 Featuring Acceleron Pharma, Biogen, Eli Lilly and Company, Fate Therapeutics & Rigel Pharmaceuticals
Business Wire - Fri Oct 23, 11:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wmzxll/muscle_atrophy) has announced the addition of the "Muscle Atrophy - Pipeline Review, H2 2015" report to their offering.
FATE: 3.73 (+0.46), LLY: 78.31 (+1.33), RIGL: 2.63 (-0.27), XLRN: 26.17 (+0.86)
Why Valeant Isn’t Enron -- or Like Any Other Drug Stock
at The Street - Fri Oct 23, 10:55AM CDT
Whether the allegations against Valeant are true or not, they shouldn't be tainting most other biotech and drug stocks. That's because Valeant is in its own unique universe.
VRX: 116.16 (+6.29), PFE: 34.05 (+0.72), ABBV: 50.34 (+2.07), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98)
Muscle Atrophy - Pipeline Review, H2 2015 Featuring Acceleron Pharma, Biogen, Eli Lilly and Company, Fate Therapeutics & Rigel Pharmaceuticals
M2 - Fri Oct 23, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z4zdzz/muscle_atrophy) has announced the addition of the "Muscle Atrophy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Acceleron Pharma, Inc. - Biogen, Inc. - Eli Lilly and Company - Fate Therapeutics, Inc. - Rigel Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/z4...le_atrophy
FATE: 3.73 (+0.46), LLY: 78.31 (+1.33), RIGL: 2.63 (-0.27), XLRN: 26.17 (+0.86)
Global Anal Cancer Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Oct 23, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5v4vqf/anal_cancer) has announced the addition of the "Anal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advaxis, Inc. - Amgen Inc. - Eli Lilly and Company - ISA Pharmaceuticals B.V. - MedImmune, LLC - Novartis AG - Sun Pharma Advanced Research Company Ltd. Drug Profiles - axalimogene filolisbac - Cell Therapy for HPV Associated Cancers - durvalumab tremelimumab - ISA-101 - paclitaxel albumin free - panitumumab - PDR-001 - prexasertib For more information visit http://www.researchandmarkets.com/research/5v...nal_cancer
ADXS: 10.77 (+0.47), AMGN: 155.75 (+3.44), LLY: 78.31 (+1.33), NVS: 92.98 (+0.55)
Sell These 5 Scary Stocks Before It's Too Late
at The Street - Fri Oct 23, 6:03AM CDT
It's time to unload these toxic stocks from your portfolio.
NFLX: 100.04 (+2.72), SAFM: 69.41 (+0.50), LLY: 78.31 (+1.33), VZ: 46.16 (+0.27), PANW: 159.20 (-6.94)
Proof-of-concept Study of Fruquintinib in Non-small Cell Lung Cancer Triggers Milestone Payment
PR Newswire - Fri Oct 23, 1:46AM CDT
Hutchison China MediTech Limited ("Chi-Med"
(AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP" , its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourth quarter of 2015, from its partner Eli Lilly and Company ("Lilly" . LLY: 78.31 (+1.33)
Eli Lilly Q3 Earnings, Guidance Beat On Cost Control
at Investor's Business Daily - Thu Oct 22, 6:09PM CDT
Big pharma Eli Lilly beat Q3 earnings expectations and raised EPS guidance early Thursday, while the company's CEO defended the industry's drug pricing. Lilly's revenue was more of a mixed bag, as the firm continues to struggle with foreign-exchange...
MRK: 52.88 (+0.87), LLY: 78.31 (+1.33), BMY: 65.16 (+1.98), NVS: 92.98 (+0.55)
Shire (SHPG) Gets CRL for Dry Eye Disease Drug from FDA
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 3:35PM CDT
Shire (SHPG) received a complete response letter from the FDA for its new drug application for lifitegrast for the treatment of dry eye disease.
ADHD: 6.73 (+0.45), SHPG: 213.55 (+9.28), LLY: 78.31 (+1.33), NVS: 92.98 (+0.55)
Lilly (Eli) & Co (LLY) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Thu Oct 22, 2:43PM CDT
The following Lilly (Eli) & Co (LLY) conference call took place on October 22, 2015, 09:00 AM ET. This is a transcript of that earnings call:
LLY: 78.31 (+1.33)
Stocks Rally as eBay, Texas Instruments Lead Tech Sector
at The Street - Thu Oct 22, 1:12PM CDT
Stocks hover near session highs by mid-afternoon Thursday after better-than-expected earnings from eBay and Texas Instruments boost the tech sector.
MMM: 155.79 (-0.21), XLB: 45.02 (+0.37), AXP: 74.59 (+2.09), FB: 102.19 (+2.52), LLY: 78.31 (+1.33), AKS: 2.66 (+0.02), PYPL: 34.99 (+0.20), INTC: 34.90 (+0.50), CTXS: 81.14 (+0.56), UA: 92.02 (-1.79), LYB: 94.16 (-0.35), EBAY: 28.16 (+0.58), BHP: 35.75 (+0.37), TXN: 58.98 (+0.89), COST: 155.74 (-2.41), MCD: 112.59 (+1.72), XLK: 43.83 (+1.19), GOOGL: 719.33 (+38.19), CAT: 71.75 (+0.87), MSFT: 52.87 (+4.84), RIO: 38.29 (+0.33), AAPL: 119.08 (+3.58), DOW: 50.32 (+0.40), BABA: 75.62 (+4.63)
Eli Lilly Beats on 3Q Earnings by Wide Margin, Ups View
Arpita Dutt - Zacks Investment Research - Thu Oct 22, 10:30AM CDT
Eli Lilly (LLY) raised its earnings outlook after posting better-than-expected third quarter earnings.
NVO: 55.72 (+2.07), AZN: 31.36 (+0.29), ABBV: 50.34 (+2.07), LLY: 78.31 (+1.33)
Stocks Jump as Europe Rallies on ECB Stimulus Hopes
at The Street - Thu Oct 22, 10:16AM CDT
Stocks extend session highs Thursday, following in the footsteps of European markets which rallied on hopes of more stimulus from the European Central Bank.
MMM: 155.79 (-0.21), AXP: 74.59 (+2.09), PYPL: 34.99 (+0.20), LLY: 78.31 (+1.33), LULU: 48.49 (-3.84), CTXS: 81.14 (+0.56), UAL: 59.68 (+3.63), UA: 92.02 (-1.79), EBAY: 28.16 (+0.58), TXN: 58.98 (+0.89), COST: 155.74 (-2.41), MCD: 112.59 (+1.72), CAT: 71.75 (+0.87), DOW: 50.32 (+0.40)
Eli Lilly (LLY) Stock Gains in Pre-Market Trading on Earnings Beat, Raised Guidance
at The Street - Thu Oct 22, 8:03AM CDT
Eli Lilly (LLY) stock is increasing in pre-market trading on Thursday, after the company announced its 2015 third quarter financial results and raised its financial outlook.
LLY: 78.31 (+1.33)
Stock Futures Rise as McDonald's Posts Surprise Beat
at The Street - Thu Oct 22, 7:42AM CDT
Stock futures are higher Thursday after better-than-expected earnings from McDonald's.
MMM: 155.79 (-0.21), AXP: 74.59 (+2.09), LLY: 78.31 (+1.33), PYPL: 34.99 (+0.20), LULU: 48.49 (-3.84), CTXS: 81.14 (+0.56), UAL: 59.68 (+3.63), UA: 92.02 (-1.79), EBAY: 28.16 (+0.58), TXN: 58.98 (+0.89), MCD: 112.59 (+1.72), COST: 155.74 (-2.41), CAT: 71.75 (+0.87), DOW: 50.32 (+0.40)
Eli Lilly (LLY) Beats on Q3 Earnings, Revenues Fall Short
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 7:00AM CDT
Eli Lilly's (LLY) third quarter earnings surpassed expectations by a wide margin.
LLY: 78.31 (+1.33)
Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Thu Oct 22, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdtss/breast_cancer) has announced the addition of the "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023. A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III) Chapter 5 Recommendations Chapter 6 Company Profiles - AstraZeneca plc - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Novartis International AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/5x...ast_cancer
PFE: 34.05 (+0.72), AZN: 31.36 (+0.29), LLY: 78.31 (+1.33), GSK: 42.11 (+0.67), NVS: 92.98 (+0.55)
Lilly beats 3Q profit forecasts
Automated Insights - Thu Oct 22, 5:33AM CDT
INDIANAPOLIS (AP) _ Eli Lilly and Co. (LLY) on Thursday reported third-quarter net income of $799.7 million.
LLY: 78.31 (+1.33)
